Cambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) ...

Cambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease ...

Leaked API keys are no longer unusual, nor are the breaches that follow. So why are sensitive tokens still being so easily exposed? To find out, Intruder’s research team looked at what traditional ...

JavaScript updates in 2026 focus on fixing long-standing issues instead of adding unnecessary complexity. Core features now handle iteration sets, async logic, and dates with fewer workarounds and ...

CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics ...

Clear and near-term value inflection points, with blinded 6-month interim data expected in Q2 2026 and final unblinded top-line results anticipated in Q4 2026 ...

Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) ...

Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s ...

Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease ...